SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " antibody " 38 found 🔀 AI-powered Shuffle
Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertain
Pfizer has called time on a phase 2 trial of its CXCR5 antibody in an autoimmune blood disorder, with the company tight-lipped on whether this marks the end of the road for the asset. The Big Pharma had been evaluating the therapy, dubbed PF-06835375, in a phase 2 study of 61 patients with primary immune thrombocytopenia (ITP) that kicked off in 2022, according to the federal trials register. However, Pfizer confirmed to Fierce on Monday that this study had been terminated “due to a business decision.” “The decision to terminate the trial was not based on any safety concerns,” a spokesperson pointed out. At time of publication, PF-06835375 remained listed on Pfizer’s website for both ITP and lupus. A phase 1 study in lupus wrapped up in 2022, according to the trials database. ITP is an autoimmune disorder characterized by a low platelet count. Novartis was at one point evaluating its B-cell-depleting antibody ianalumab—recently approved as Fabhalta to treat immunoglobulin A nephropathy—as a potential treatment ITP. But the therapy struggled to demonstrate a benefit in the clinic for this indication. When contacted by Fierce, Pfizer wouldn’t confirm whether all work on PF-06835375 has been halted, and whether the company has any other plans to explore C-X-C chemokine receptor type 5 (CXCR5) as a mechanism. CXCR5 is found in blood cancers such as diffuse large B-cell lymphoma and mantle cell lymphoma chemokine receptor. However, there is little expression in normal tissue, which has led some drug developers to explore its potential. Vincerx Pharma had at one point been planning to take an anti-CXCR5 ADC into the clinic to treat B-cell malignancies, but that ambition was scrapped due to cash constraints. Where Big Pharma is placing its bets is one of the hot topics being discussed at Fierce Biotech's high-impact event in London next month. Find out more information and register by clicking on the banner below: [ ](https://qtxasset.com/quartz/qcloud5/media/image/where_big_pharma_is_placing_its_bets.png?VersionId=B8JrRbJ.pFUSK1pJgjeWHLGm_18RdLAy)
Bora Biologics and Protect Animal Health Enter Strategic, Long-Term Multi-Project Collaboration to Advance Antibody-Based Animal Health Products
Partnership includes development and manufacturing support for multiple monoclonal and bispecific antibody programs targeting U.S. and global animal health markets
Bora Biologics and Protect Animal Health Enter Strategic, Long-Term Multi-Project Collaboration to Advance Antibody-Based Animal Health Products
Partnership includes development and manufacturing support for multiple monoclonal and bispecific antibody programs targeting U. and global animal health marketsSAN DIEGO, CA AND TAIPEI CITY, TAIWAN / ACCESS Newswire / October 4, 2026 / , a U.
Bora Biologics and Protect Animal Health Enter Strategic, Long-Term Multi-Project Collaboration to Advance Antibody-Based Animal Health Products
Partnership includes development and manufacturing support for multiple monoclonal and bispecific antibody programs targeting U.S. and global animal health markets
California firm licenses ‘potent’ anti-measles antibodies from Vanderbilt Health for development, clinical testing
Further development could lead to the first monoclonal antibody therapy against the highly infectious measles respiratory virus.
Philadelphia Health Officials Warn Of Possible Measles Exposure At Children’s Hospital
Infants who were potentially exposed to the extremely contagious airborne virus are being given a preventative antibody product.
Philadelphia health leaders warn of possible measles exposure reported at CHOP’s NICU
Officials said they’re working to administer a preventative antibody treatment to all infants in the NICU to help protect them from measles.
Harvard scientists design evolutionary traps to stop viral mutations
When a virus mutates, the world usually finds out the hard way. Variants of influenza and SARS‑CoV‑2 can slip past vaccines and antibody drugs before scientists fully understand what has changed.
Scientists Create New Antibody For Virus That Infects 95% of People
A crucial milestone.
Four Japanese scientists win prestigious U.S. Lasker Awards
One received the prize for his work on a sleep-regulating brain chemical, and a trio, for discovering an antibody therapy for hemophilia A patients.
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
With a detailed data drop that AstraZeneca’s R&D chief described as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become a flagship biologic in chronic obstructive pulmonary disease (COPD). In detailed results from the late-stage Oberon and Titania trials—first teased in March and detailed in full at the European Respiratory Society Congress in Barcelona this week—the drugmaker laid out the extent of its IL-33 inhibitor’s potential to reduce moderate and severe exacerbations in a wide range of COPD patients still struggling with those “lung attacks,” as AstraZeneca’s Sharon Barr, Ph.D., called them, despite using standard-care inhaled therapy. In the headline results, a 300 mg dose of tozorakimab given once every four weeks curbed those moderate and severe exacerbations in the studies’ primary population of former smokers by 29% in the Oberon study and 34% in Titania. In the overall population of both current and former smokers, these reductions were 30% and 29%, respectively, versus placebo and inhaled standard of care. The benefits also extended to clinically meaningful exacerbation reductions in all prespecified patient subgroups and specifically turned up promising signals in patients across a range of blood eosinophil counts, with Barr telling Fierce that “it’s the details that make this even more exciting than the high-level results that we’ve already shared.” In fact, during AZ’s tozorakimab poster presentation at the ERS 2026 Congress this past weekend, attendees were so enamored by the data that event organizers had to encourage people to clear the room and look at the other presentations on offer, Barr said in an interview. “I think it really speaks to the fact that there is a lot of buzz around these data because the entire respiratory community has been so desperate for new therapies for these patients,” she explained. The respiratory disease continues to represent a “staggering unmet medical need,” Barr said, highlighting the COPD exacerbations that the Oberon and Titania studies homed in on, which she added carry a greater mortality risk than a heart attack. “When a patient has a severe exacerbation, only about half of them are still alive within three and a half years,” she pointed out. As for tozorakimab specifically, Barr christened the molecule “an AstraZeneca science success story,” harkening several years back to the point at which researchers began to explore IL-33 as a driver of respiratory disease, and COPD in particular. At the same time, “there was still so much that wasn’t understood,” she admitted, highlighting the insight that IL-33 signals through both ST2 and EGFR through the RAGE pathway, a discovery Barr attributed to AstraZeneca's own scientists. Understanding the need to tackle both pathways in COPD—and aware of competitor candidates in the hopper, including one that bound ST2—the company ultimately had to make some “courageous decisions,” Barr said. These included taking a prior COPD molecule offline and going back to the drawing board to reinvent its potential IL-33 label “to make sure that we had a molecule that could block signaling through both arms of the pathway, through both the reduced form and the oxidized form, knowing that we wouldn’t be first, but striving to be best.” “When we put [tozorakimab] into the clinic, we firmly believed that we had a differentiated molecule, and we saw the other molecules blocking just ST2 or partially blocking IL-33, unable to deliver two positive pivotal studies in COPD,” Barr explained. “We kept marching forward because we believed our molecule was differentiated, and now I think we have the clinical validation that supports that.” Ultimately, AstraZeneca finds itself on much better footing these days when it comes to potential biologic rivals to tozorakimab in COPD. Sanofi and Regeneron’s Dupixent, for instance, is approved to treat COPD exacerbations in patients with high eosinophil counts, but not low ones. Meanwhile, the future has become cloudier for other next-gen IL-33 candidates from Sanofi and Regeneron, as well as Roche, which have suffered trial flops in recent years. One other potential ingredient for AstraZeneca’s success in its duo of studies was that the company was “ambitious in the trial design, willing to look at an all-comers population,” Barr said, “and willing to enroll the most severe patients.” Prior studies for would-be biologics rivals in COPD “avoided enrolling” those patients, she pointed out. She also highlighted the Big Pharma’s painstaking design of exacerbations in its trial, which “gave us a very rigorous readout,” and pointed to “the extra effort and investment” the company put in to understand the effect of mucus plugs in patients. Barr described mucus production as a “key feature in disease diversity,” noting that mucus plugs—obstructing clumps of mucus that block patients’ airways—are associated with worse outcomes in COPD. In its data announcement, AstraZeneca noted that an integrated analysis of Oberon and Titania found tozorakimab “demonstrated a reduction in patients’ mucus plug score,” with the pharma claiming its biologic is the first to deliver such results in a broad COPD population. “So being able to reduce those mucus plugs, we expect, is an important part of driving benefit for patients who are living with COPD,” Barr said. Again touching on the breadth of the study populations, Barr added that tozorakimab “worked across all eosinophil levels in both current and former smokers across all levels of lung function,” which she suggested “really simplifies decision-making for clinicians, and it allows them to offer therapy to the broadest possible patient population.” In the highest patient eosinophil count group, tozorakimab helped chart a 43% reduction in exacerbation risk, which Barr stressed were “unprecedented data.” In the mid-level group, AZ’s drug delivered a 23% reduction and, in the lowest group, a 34% reduction in eosinophils, which Barr said suggests efficacy “in all patient subgroups.” As for AZ’s recent guidance upgrade on the medicine’s sales opportunity, the lift from a $3 billion to $5 billion range to $5 billion plus was informed by multiple factors, Barr said, including the fact that “in 2024, there were multiple competitors, and there aren’t anymore.” Additionally, “we know that this is a massive unmet medical need, and this is a really incredible set of data that we think will be very convincing to the clinical community,” Barr said. Looking ahead to a potential evolution of the COPD treatment landscape, Barr noted that most patients start treatment in the community with an option like a triple therapy, and for them, having an option like AstraZeneca’s inhaler Breztri will remain a “really important part” of that journey. But of the patients uncontrolled on triple therapy, which Barr described as “about half of them today,” just a “small fraction” are currently eligible for biologic therapy, which she emphasized AstraZeneca is working to change. Understanding that COPD is not a “one-size-fits-all” disease, AstraZeneca is also looking at its antibody drug Tezspire for patients with T2-driven disease, and the company continues to think about new mechanisms for tackling COPD through both systemic and inhaled drugs, Barr said.
Supercharged “natural killer” cells could be a powerful new cancer weapon
Researchers have found a way to supercharge natural killer cells, powerful immune cells that can attack cancer, so they can penetrate solid tumors and keep fighting once inside. In mice, these specially prepared tissue-resident cells slowed the growth of several tumors, including melanoma and head and neck cancers, and worked even better when paired with the antibody drug cetuximab.
AI may know how you’ll respond to a vaccine before you get it
AI may be able to predict how strongly someone will respond to a vaccine before they receive it. By analyzing antibody patterns in more than 4,000 people, researchers found signs of “immune readiness” that helped distinguish strong responders from weak ones. Surprisingly, even some healthy people responded poorly, while some immunosuppressed people mounted strong responses.
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women’s health market. The phase 2 clinical trial compared ABCL635, an antibody targeting NK3R, to placebo in patients with hot flashes caused by menopause. Investigators enrolled 92 postmenopausal women experiencing a mean of about 10 moderate or severe hot flashes per day. By Week 4, the number of moderate or severe hot flashes had fallen by a mean of 8.8 on ABCL635 and by 3.5 on placebo. That statistically significant, placebo-adjusted reduction of 5.3 hit the trial’s primary endpoint. The level of efficacy also cleared the bar set by existing drugs. While cross-trial comparisons can be misleading, AbCellera CEO Carl Hansen, Ph.D., had seen enough to start hyping the program. “We now view ABCL635 as a potential best-in-class non-hormonal therapy with strong differentiation against approved NK3R competitors across all important dimensions, including efficacy, safety, dosing and convenience,” Hansen said on a Monday morning conference call with investors to discuss the data. “We believe ABCL635 is now a highly de-risked program.” Last week, Hansen used AbCellera’s earnings call to set expectations for readout, with the CEO defining success as a clean safety profile and efficacy comparable to the two approved small molecules. The data vaulted over that bar. Astellas linked (PDF) one of the small molecules, Veozah, to placebo-adjusted reductions in hot flash frequency of 2.1 and 2.6 at Week 4 of its two phase 3 trials. Bayer reported (PDF) placebo-adjusted reductions of 3.04 and 3.29 at Week 4 of pivotal studies for its small molecule, Lynkuet. At 5.3, the placebo-adjusted reduction in AbCellera’s trial comfortably cleared the standard set by the incumbents. Veozah and Lynkuet came to market based on evidence of their ability to reduce the frequency and severity of hot flashes. AbCellera’s phase 2 study covered both endpoints, with the Canadian biotech reporting a mean reduction in severity of 1.4 points at Week 4 on ABCL635, compared to 0.3 points for placebo. Again, the placebo-adjusted result compares favorably to data on Veozah and Lynkuet. Analysts shared Hansen’s enthusiasm for the data. The phase 2 results “firmly validate ABCL635 as a potentially best-in-class treatment,” BMO Capital Markets analysts said in a note to investors Monday. ABCL635’s apparent efficacy edge “is likely attributable to the higher dosing/target engagement the asset is able to reach vs. the oral agents due to its wider therapeutic index,” the analysts added. The analysts, who model $2.3 billion in unadjusted peak sales for ABCL635, flagged the safety profile as another positive of the phase 2 readout. While Veozah carries a boxed warning for liver damage, nobody on ABCL635 in the phase 2 trial had elevated liver enzymes or bilirubin values. If replicated in phase 3, the lack of a liver signal could allow approval without the monitoring requirements imposed on Veozah. Investors appeared equally enthused, sending AbCellera's stock up 32% to $9.21 in premarket trading Monday from a Friday closing price of $6.93. Next, AbCellera will collect the Week 12 data and talk to its advisors about further development. The results open up “a wide variety of possibilities of how we might take this forward into phase 3 studies to truly maximize the value of the asset and make sure that ABCL635 is able to demonstrate its differentiation potential,” Sarah Noonberg, M.D., Ph.D., AbCellera’s chief medical officer, told investors.
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has learned. The trial, which began only back in April, was a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score following treatment with SAR445399 compared with placebo in adults aged 18 to 80 years with NCFB, a chronic lung disease. The trial was officially reported as halted on July 29, the day before Sanofi’s second-quarter earnings call. The decision to pause the trial was made “as part of a company-wide portfolio review for strategic business reasons,” and not due to safety concerns, a Sanofi spokesperson told Fierce. The move to pause the NCFB trial comes during a trying time for Sanofi following a year filled with a series of trial fails. In February, the French pharma ousted CEO Paul Hudson and appointed Merck KGaA leader Belén Garijo, M.D., Ph.D., to steer the ship. Since then, Garijo has been doing a deep dive on correcting the company’s strewn R&D and clinical strategies. On July 24, Sanofi scrapped amlitelimab for atopic dermatitis, despite its lore as being a potential $5 billion blockbuster. During its second-quarter report, the company abandoned two more assets, balinatunfib and itepekimab, following failed trial results in psoriasis and chronic obstructive pulmonary disease, respectively. SAR445399, only first revealed by Sanofi in 2023, is an anti-interleukin-1 receptor 3 monoclonal antibody developed to block the interleukin 1, 33, and 36 cytokine pathways. These pathways can be important in chronic immune-related dermatologic diseases, such as atopic dermatitis and hidradenitis suppurativa, as well as respiratory conditions, such as NCFB. Related Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues NCFB affects roughly half a million people in the U.S., with a global incidence of greater than one million cases. In August 2025, Insmed received FDA approval for Brinsupri, a DPP1 inhibitor targeting neutrophil activation, for treatment of NCFB in adults and kids ages 12 and older. The British biotech Infex Therapeutics showed promising NCFB phase 2a data using their monoclonal antibody, INFEX702, which acts by disabling Pseudomonas aeruginosa, a bacteria known to be a major pathogen of NCFB. Sanofi is currently running a separate phase 2 study testing SAR445399 as a potential treatment for the inflammatory skin condition hidradenitis suppurativa.
A unique antibody system may help explain bats' unusual tolerance of viruses
Researchers found that vesper bats use two separate sets of genes to build antibodies — a rare evolutionary quirk that may give them different ways to fight infection.
Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Positive results from the MULBERRY Phase III trial showed that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, demonstrated a statistically significant and clinically meaningful improvement in bone health in children (2 to
Another look at carrots and eyesight; how to get more fiber; why mosquitoes bite some people and not others; plus other stories with Vanderbilt Health sources
AARP reporter Stacey Colino interviewed Milam Brantley, MD, Associate Professor of Ophthalmology and Visual Sciences, in 2020 for a story about whether eating carrots can improve vision. Sacramento Bee reporter Samantha Agate has now used Brantley’s comments in an AI-curated story created by content specialists on the same topic that has been picked up by MSN and others. Prevention magazine interviewed Heidi Silver, RD, PhD, Founding Director of the Vanderbilt Diet, Body Composition, and Human Metabolism Core, for a story about the importance of fiber and how people can get more of it in their diet. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: Women’s Health (tick bites and alpha-gal syndrome); The Washington Post (tetanus); and Healthline (why mosquitoes prefer to bite some people and leave others alone). A visit to Monroe Carell Jr. Children’s Hospital at Vanderbilt by some Banana Ball baseball players was covered by The Tennessean and WZTV Fox 17 News, and The Tennessean’s story was also picked up by Yahoo! Sports. Clarksville Now published a story written by the Montgomery County Economic Development Team, whointerviewed Bradley Stancombe, MD, professor of Clinical Pediatrics, Vanderbilt Neonatology, about the new energy of Vanderbilt Clarksville Hospital and how the facility is recruiting physicians. Healio Allergy/Asthma group editorial director Richard Gawel interviewed Mark Rolfsen, MD, Clinical Fellow in the Division of Allergy, Pulmonary and Critical Care Medicine, for a story about his presentation at the American Thoracic Society meeting on metal health outcomes following ICU discharge. Nashville Scene reporter Hannah Herner interviewed James Crowe, MD, Director of the Vanderbilt Center for Antibody Therapeutics, for a story about his efforts to prepare for the next pandemic by isolating antibodies that can neutralize dangerous viruses. Medscape reporter Kathleen Doheny interviewed Neesha Choma, Associate Chief of Staff of Vanderbilt University Hospital, for a story about how hospitals can reduce readmissions.
Breaking Business News: AbbVie To Acquire Apogee Therapeutics
AbbVie is set to acquire Apogee Therapeutics and its pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including its lead asset, zumilokibart (APG777), a subcutaneous half-life extended monoclonal antibody targeting interleukin (IL)-13 in atopic dermatitis (AD). Under the terms of the transaction, AbbVie will acquire all outstanding shares of Apogee for $135.11 per share in cash. […]
Using AI for medical advice; pelvic floor exercises; the hidden dangers of burning incense; plus other stories with Vanderbilt Health sources
Colin Walsh, MD,Associate Professor of Biomedical Informatics, was on WTVF News Channel 5‘s “Morningline” show in an interview about whether or not it is safe to use AI for medical advice. Time magazine reporter Stacey Colino interviewed Elisabeth Sebesta, MD, Assistant Professor of Urology, for a story about pelvic floor exercises for issues including menopause, erectile dysfunction and urinary incontinence in men. “Each Breath,” published by the American Lung Association, quoted Brian Christman, MD, Adjunct Professor of Medicine, for a story about the hidden dangers of burning incense. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: Healthline (low vaccination rates lead to more cases of measles, whooping cough and other preventable diseases); ABC News (U.S. measles cases surpass 2,000 for second year in a row); and CIDRAP News (high-dose flu shots cut rates of hospitalization in older adults). Sarah Rohde, MD, Associate Professor of Otolaryngology-Head and Neck Surgery, was quoted in a People magazine story on patient Makalii Andrade, a surfer from Kauai Island who suffered a serious neck injury in 2022 and recently underwent surgery at Vanderbilt Health to begin the final phase of his recovery. James Crowe, MD, Director of the Vanderbilt Center for Antibody Therapeutics, for a piece in Nature about antibodies against a strain of Ebola. SFGATE reporter Gillian Mohney interviewed Xue Zhong, PhD, Research Assistant Professor, Division of Genetic Medicine and Clinical Pharmacology, for a story about a study of a blood test looking at Alzheimer’s disease biomarkers. Matthew Franklin Mart, MD, Assistant Professor of Medicine, was quoted in a Healio story about how inflammation and illness severity is linked to less cognitive resilience after a person has been an ICU patient. The “How We Really Feel” podcast host Sula Windgassen, PhD, interviewed Lindsey C. McKernan, PhD, MPH, Associate Professor of Psychiatry & Behavioral Sciences, Physical Medicine & Rehabilitation and Urology, for an episode focusing on pelvic and bladder health. The podcast is also available on YouTube and the podcast website. In addition, podcaster Monica Sanford interviewed cardiologist Mark Glazer, MD, for her podcast “The Monica Sanford Show”; the two-part interview is here and here.
A drug may help people on GLP-1 meds preserve muscle
In a clinical trial, an experimental antibody reduced lean-mass loss in people on a GLP-1 drug. Whether that improves health is unclear.
E-bike safety; lung cancer treatment and prevention; keeping CMA Festival attendees safe; plus other stories with Vanderbilt Health sources
WKRN News 2 interviewed Jeffrey Upperman, MD, FACS, Professor and Chair of the Department of Pediatric Surgery and Surgeon-in-Chief of Monroe Carell Jr. Children’s Hospital at Vanderbilt, about e-bike related injuries following the recent death of a Brentwood High student and a proposal to require safety training before students could ride a bike on a school campus in Williamson County. Fabien Maldonado, MD, MSc,Professor of Medicine and Thoracic Surgery, was on WTVF News Channel 5‘s live studio show, “Openline,” with host Ben Hall, to discuss lung cancer, treatment and prevention. WSMV’s “Today In Nashville” program hosted Vanderbilt LifeFlight paramedic/flight nurse practitioner Tony Smith to talk about safety for the CMA Festival. The New York Times reporter Carl Zimmer interviewed James Crowe, MD, Director of the Vanderbilt Center for Antibody Therapeutics, for a story about the race to find vaccines and treatments as Ebola spreads. The Vanderbilt Health News release about the pilot clinical trial conducted by Vanderbilt Health and Cumberland Pharmaceuticals Inc., that confirms the safety of ifetroban and supports the further development of the drug to prevent cancer metastasis, was picked up by Reuters, Stock Titan,and others. Women We Admire has named Lee Ann Liska, President and Chief Operating Officer, to its list of top women leaders of Nashville for 2026. Radiology Business, Aunt Minnie, Bioengineer, and Imaging Technology News covered the study from Consuelo Wilkins, MD, MSCI, the Mildred Thornton Stahlman Professor in Rural Health and professor of Medicine in the Division of Geriatric Medicine, that found Black and Hispanic people, while known to be far more apt to have dementia, are significantly less apt than other racial and ethnic groups to show Alzheimer’s pathology on brain scans. STAT News interviewed Deva Sharma, MD, Transfusion Medicine & Hematology-Oncology, for a story about more patients requesting unvaccinated blood and what it means for the medical system at large. Yahoo! Health reporter Korin Miller interviewed Gitanjali Srivastava, MD, Director of Obesity Medicine, for a story about how semaglutide and tirzepatide compare. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: NBC News (new COVID vaccinations); Medscape (pneumonia and sepsis); and CNN (protection from contagious viruses). Shelbyville Times-Gazette is repurposing Jessica Pasley’s July 2025 Vanderbilt Health News story on tick-borne illnesses as a front-page story.
Vanderbilt Health researchers call for pandemic prevention through antibody development
The next pandemic may arrive in the United States via cruise ship or commercial flight originating halfway around the world.
Ebola, chemical plants and health, hantavirus, common colds, heat and more
As they say, bugs have ears. Public health has had a relentless May. Chemical plant (near) explosions, Ebola, hantavirus, and that's before you even get to the usual suspects: common colds, heat, and ticks. Here’s an attempt to keep you up to speed and, more importantly, what it means for you and your community. But first, an announcement: World Cup The World Cup starts in 15 days (not like anyone is counting down), and we are hanging TVs in the Health Security Operations Center. It’s going to be a gorgeous, chaotic celebration of basically every culture on earth. And it’s going to take a team effort—from communities to individuals, from public health to health care—to keep people healthy. That’s where you come in. If you’re going to the games or live within 30 miles of a stadium, we would love to hear from you. Sign up for a weekly survey here. Thanks to the more than 1,280 people who have already signed up…you will be hearing from us soon!! Global disease “weather report” Hantavirus: Two more cases The global count of cruise ship passengers with hantavirus has now increased to 13 cases (11 confirmed), with three deaths. The two new cases are overseas and among people who were already quarantining: A crew member in the Netherlands. A Spanish national passenger who was quarantining at home tested positive through daily monitoring. They are now in a biocontainment unit. In the U.S., everyone remains negative. There may be more cases, given that the incubation period of hantavirus (the time from exposure to infection) is 45 days. But this week, we will reach a major milestone: the median incubation window is 18 days, and that will pass on May 29. What this means for you: Your risk from this cruise ship outbreak remains essentially nil at this point. Ebola rages on in Central Africa Big thanks to Dr. Craig Spencer, a humanitarian physician who has treated and survived Ebola, for jumping in to provide the YLE community with an update. Craig, take it from here… The combined confirmed and suspected Ebola cases in DRC are now more than 1,000. All signs are pointing to a very long and catastrophic outbreak in Central Africa: This is a vast undercount. We know this because the test positivity rate is hovering around 50%, only 20% of contacts are being traced (and in some areas, no contacts at all), and more cases keep popping up with no known connection. This all points to widespread and undetected community transmission. This is in only a week of detection. Compared to previous outbreaks, the growth is very fast, as the huge West Africa outbreak in 2016 was first detected at 49 cases and rose to 208 cases a month later. It took four months for that outbreak to reach the size of the current one in the DR Congo. The cases are spread out across 16 health zones. There are now multiple epicenters, making containment very difficult. Next door in Uganda, the case count is seven. While this number is low compared to DRC, a concerning development is that two health care workers recently tested positive with uncertain exposure histories. If they weren’t treating known Ebola cases, this means it’s spreading undetected in Uganda as well. On the ground, backlash, including the burning of health centers, has emerged, a pattern seen in nearly every outbreak and rooted in deep community distrust. It often stems from outside actors working in communities without fully understanding or addressing local priorities. Affected populations may recognize the severity of Ebola while still holding other concerns as more pressing, such as where their loved ones are buried. Community trust is essential to an effective response, but difficult to build during an active emergency. It is best established long before a crisis begins. U.S. priorities are made clear, and may backfire. The U.S. Administration has shown that its first priority is keeping Ebola out, with helping end the outbreak in the DRC a secondary concern. That's meant travel restrictions broader than anything we've imposed before — covering travelers from across the region, and reportedly some green card holders and permanent residents as well. For example, just these past two days, news broke that high-risk American travelers will be subject to a mandatory quarantine in Kenya before they are allowed to return. If an American is infected, the U.S. government plans to send them to a hospital it is standing up from scratch in Kenya. (Currently, Americans who were in the area are allowed to return but are diverted to three airports—Houston, Atlanta, and DC—for further screening.) Past administrations have used travel notices and stepped-up screening; this goes much further. At first blush, these strict precautions may sound prudent. But this approach could backfire in three ways: Restrictions this blunt give people every reason to hide where they’ve been and whom they’ve been near — making the people we most need to find harder to track, not easier. They also breed a false sense that this is someone else’s problem. But diseases are humbling. They find the small cracks in even the most impenetrable-seeming defenses. Lives lost. There is no treatment for this Ebola strain, which means survival depends heavily on the quality of the health system. We have that system in the States, but we are choosing not to use it for infected Americans. This is unbelievable and infuriating. (See a deeper dive from me here.) The only real way to lower the risk to Americans — and everyone else — is to end the outbreak in the DRC and across the region. What this means for you: If you have travel plans to this region, it’s time to cancel them. This is a high-risk situation in Central Africa, and CDC released a Level 4 Travel Advisory. There is also great uncertainty if and when the Administration will let you back in. To the general public in the U.S., your risk remains very, very low right now. U.S. disease “weather report” Ticks: past peak season? Good news, especially for people in the Northeast and Midwest: tick numbers continue to decline. Though we are at the peak of the season, this unusually early year is trending favorably. Heat-related illnesses in the North Heat risk is certainly not blanketing the entire country yet, but this week it will be moderate in the Midwest and the Southeast. What this means for you: Be sure to check the CDC HeatRisk tool. A red day isn’t the best day for that soccer game for a kid with asthma, and a stretch of orange days is a great time to check on your elderly neighbor. Common colds surging As far as respiratory viruses go, the only thing really going around right now is the common cold. It is higher this year than last year, but should peak very soon before returning this fall. Spotlight: Chemical plants Over the weekend, YLE California covered the serious situation that unfolded around a chemical plant in Orange County, California. Thankfully, the worst-case scenario (a chemical explosion) was mitigated, but only through luck. The health implications in a densely populated area could have been catastrophic. As the situation was winding down, another chemical explosion struck Washington State. This one was fatal. Health officials say the risk to surrounding residents from chemicals in the air and ground remains low, though the community deserves far greater clarity. Clean air and clean water consistently rank as Americans’ top public health concerns — yet when chemical disasters strike, communities are too often met with reassurances rather than transparency and accountability. Residents near the 2023 East Palestine, Ohio train derailment, for example, are still waiting to understand the long-term impact on their health, with few clear answers. What this means for you: Many are wondering if facilities processing potentially dangerous materials are in their neighborhoods. This interactive map allows you to enter your ZIP code and see all facilities monitored by the EPA, including any violations. Good news Ebola vaccines and treatment for the Bundibugyo species are in development. Two vaccine platforms are being explored, at least one of which may be deployable in as little as 2 months. One vaccine is being developed by Oxford, and the other uses the same biotechnology as the FDA-approved Zaire species of Ebola. (It may provide cross-protection, but it’s unclear at this point.) On the treatment side, two promising monoclonal antibody cocktails are likely to be deployed, though doses are limited and logistical hurdles remain significant challenges. Anni over at The Biotech Tea had a great explainer about the Ebola vaccine gap, if you want to read more. [ The Biotech Tea The Ebola vaccine gap, reading vessel damage, & the Makary exit 🗝️ Paid subscribers get the Biotech Term of the Week at $30/year (~$2.50/month). I try to keep it intentionally accessible, but if cost is ever a barrier, send me a message. A few people asked about expensing your subscription, so I put together a short email template… Read more 6 days ago · 10 likes · Annicka Evans, PhD ](https://www.thebiotechtea.com/p/the-ebola-vaccine-gap-reading-vessel?utm_source=substack&utm_campaign=post_embed&utm_medium=web) Polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS), following more than a decade of debate and input from roughly 22,000 clinicians, researchers, and patients worldwide. This is good because the old name was medically misleading, leading to patients without visible cysts being dismissed or overlooked entirely. The WHO estimates that 70% of people with the condition remain undiagnosed. A more accurate name should improve recognition, reduce stigma, and ultimately help the millions of people living with this condition get diagnosed and treated sooner. Poll Loading... Bottom line Public health situations are everywhere right now. Staying healthy takes public health professionals and systems working tirelessly behind the scenes and each of us showing up for our neighbors and communities. Love, YLE Big thanks to Ed Nirenberg for staying on top of the Ebola vaccines, Hannah Totte for all the figures, Dr. Craig Spencer for the Ebola insight, and Dr. Matt Willis for covering the chemical situation in CA. Your Local Epidemiologist (YLE) comprises a team of experts, ranging from physicians to immunologists to epidemiologists to nutritionists, working together with one goal: to “Translate” ever-evolving public health science so that people are well-equipped to make evidence-based decisions. YLE suite of newsletters reaches over 475,000 people across more than 132 countries. This newsletter is free to everyone, thanks to the generous support of fellow YLE community members. To support the effort, subscribe or upgrade below: Subscribe
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson Azoulay as Chief Business Officer. Mr. Azoulay joins Pyxis Oncology with more than 15 years of experience in corporate strategy, business development, and value-creating transactions across the biopharma industry, including deep antibody-drug conjugate (ADC) experience. In his role,
Science: A novel gene-therapy approach to ‘functionally cure’ HIV succeeds in some monkeys
Six animals suppressed AIDS virus after one shot of treatment that makes cell-receptor antibody
Scientists Develop New Antibody For Virus That Infects 95% of People
A crucial milestone.
Scientists Develop New Antibody For Virus That Infects 95% of People
A crucial milestone.
95% of people carry this virus and scientists may have just found how to stop it
Scientists have taken a major step toward stopping Epstein-Barr virus (EBV), an extremely common infection linked to cancer and chronic disease. By using mice engineered with human antibody genes, researchers created powerful human-like antibodies that block the virus from attaching to and entering immune cells. One of these antibodies completely prevented infection in lab models with human immune systems, marking a breakthrough after years of difficulty tackling EBV’s ability to invade nearly all B cells.
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
Successful transformation to global biotech platform with two mid-stage potential best-in-class/first-in-class programs, givastomig and VIS-101, with compelling proof-of-concept dataGivastomig, a potential best-in-class/first-in-class Claudin 18.2-directed bispecific antibody for gastric cancer, has shown robust and durable responses with broad CLDN18.2 activity, favorable safety, as well as potential eligibility for FDA’s Accelerated Approval Pathway with potential initiation of a registrationa
Doctors worry about FDA scrutiny of RSV shots to protect babies
The antibody shots are about 80% effective at preventing babies from ending up in intensive care because of RSV. The drugmakers behind them maintain they're safe.
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
$1.3 billion in fourth quarter and $4.2 billion in full year global product net sales, representing 90% year‑over‑year growth Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action date of May 10, 2026 for anti‑AChR antibody‑negative (“seronegative”) gMG Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 26, 2026 7:00 AM CET Am
NextCure Provides Business Update
SIM0505 (CDH6 ADC) Phase 1 dose escalation data update anticipated in Q2 2026LNCB74 (B7-H4 ADC) Phase 1 dose escalation expanded into higher dose cohorts BELTSVILLE, Md., Jan. 23, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today provided updates for its two antibody drug conjugate (ADC) programs and reported a preliminary year-end 2025 cash position. SIM0505 (CDH6 ADC): Phase 1 dose e
More Texans have signed up for ACA health coverage despite expiring subsidies and falling national enrollment
The Jan. 3 snapshot, though incomplete, indicates a stabler marketplace and less coverage loss than many experts and insurers feared.
MIT scientists strip cancer of its sugar shield
Scientists at MIT and Stanford have unveiled a promising new way to help the immune system recognize and attack cancer cells more effectively. Their strategy targets a hidden “off switch” that tumors use to stay invisible to immune defenses—special sugar molecules on the cancer cell surface that suppress immune activity. Early tests show it can supercharge immune responses and outperform current antibody therapies.
New trial at UC Davis Health shows promising results for rare liver disease
A new monoclonal antibody for a rare liver disease, primary sclerosing cholangitis, showed promising efficacy in a recent multicenter study led by UC Davis Health.
AI Prognosis: Were experts right about their 2025 health AI ‘bingo cards’?
AI Prognosis newsletter readers weigh in on 2025 predictions about ambient scribes, antibody design, AI agents, and more.